Article

Moderation of dose, duration key in limiting toxicity of intracameral medications, physician recommends

Chicago—Intraocular lidocaine and corticosteroids can be valuable adjuncts to the cataract surgeon, but they must be used carefully because any drug in an excessive amount can have toxic consequences, said James P. Gills, MD, at Spotlight on Cataract Surgery in 2005 during the annual meeting of the American Academy of Ophthalmology.

"While it is desirable to put our medications as close as possible to the area where they are needed, it is important to consider the dose and the time they are allowed to remain in the eye. To minimize risks, use intraocular lidocaine and corticosteroids judiciously with a moderate dose and careful control of exposure duration," said Dr. Gills, clinical professor of ophthalmology, University of South Florida, Tampa.

Lidocaine has been used intraocularly during cataract surgery on a routine basis since 1995. However, both excessive concentration and duration of exposure can result in toxic anterior segment syndrome (TASS). Dr. Gills explained that several pieces of evidence link intraocular lidocaine to the development of TASS.

Similarly, while the potential benefits of intracameral triamcinolone during cataract surgery are high for both the provider and patient, careful dosing is important. Although this corticosteroid has been used intracamerally in doses of up to 25 mg, the desired anti-inflammatory effect can be achieved with a dose of only 0.5 mg.

"The duration of action will be shorter but the trade-off is a much better safety profile," Dr. Gills said.

To maximize benefits and minimize risks of intracameral triamcinolone, he advocated keeping the dose below 2 mg, adding ascorbic acid to the irrigating solution because it seems to reduce the possibility of endothelial cell loss, and using adjunctive subconjunctival and topical corticosteroids for supplemental anti-inflammatory treatment.

"Most patients who receive intracameral triamcinolone probably do not require a corticosteroid postoperatively, but to assure adequate coverage we routinely prescribe topical treatment after surgery," Dr. Gills said.

He noted that an IOP response to steroids occurs less frequently with use of intraocular versus topical corticosteroid; however, there appears to be a higher incidence of pressure spikes in glaucoma patients that seems to increase with the dosage. Use in glaucoma patients indicates that exposure to 1 mg of intraocular triamcinolone results in a decrease in IOP, while a 2-mg dose can cause IOP to increase 6%, and exposure to triamcinolone 4 mg leads to a 40% increase in IOP.

"Nevertheless, the IOP elevation is transient and has not led any patient to undergo glaucoma surgery," Dr. Gills said.

Other potential problems include initial blurred vision and corneal edema if a concentrated amount of triamcinolone is delivered near the cornea. The findings may mimic hypopyon and lead to evaluation and treatment for endophthalmitis.

"We have now encountered five cases of pseudoendophthalmitis in patients who underwent routine cataract surgery with topical anesthesia and intraocular triamcinolone. The corticosteroid dose was excessive in one patient, but the others received a routine dose," Dr. Gills said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.